Last reviewed · How we verify
THALLOUS CHLORIDE
At a glance
| Generic name | THALLOUS CHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1977 |
Approved indications
- Myocardial perfusion imaging
- Localization of parathyroid hyperactivity
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
- Chills
- Fever
- Sweating
- Injection site burning
- Injection site pain
- Injection site redness
- Injection site swelling
- Injection site warmth
Serious adverse events
- Myocardial infarction
- Arrhythmia
- Hypotension
- Bronchoconstriction
- Cerebrovascular events
- Anaphylaxis
- Shortness of breath
- Tissue damage with chronic ulcer formation
- Hypersensitivity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THALLOUS CHLORIDE CI brief — competitive landscape report
- THALLOUS CHLORIDE updates RSS · CI watch RSS